Medical Field: Gynecology
Award: Winner
Country: Slovenia
Year: 2021
Research Work: Tie-2, G-CSF, and Leptin as Promising Diagnostic Biomarkers for Endometrial Cancer: A Pilot Study
Published in: Journal of Clinical Medicine


I am honoured to be in such an eminent company of finalists.


Luka Roškar, MD, is a finalist in the field of Gynecology. He is an Ob/GYN specialist who currently works at the General Hospital in Murska Sobota, Slovenia. He is also an assistant at the Faculty of Medicine in Ljubljana. The nomination means a lot to him and he is glad that his work has been recognised. 

His areas of interest are the diagnosis and treatment of precancerous and cancerous gynaecological tumours through a minimally invasive approach, for which he has completed the ESGE certification for Minimal invasive gynaecological surgeon. 

Endometrial cancer is the most common gynecologic malignancy in developed countries. Currently, its diagnosis requires relatively invasive endometrial histology, as there are neither valid, accurate non-invasive diagnostic methods nor tailored therapeutic methods. It is known that any cancerous tissue larger than a few millimetres requires the formation of new vessels for its growth (angiogenesis). To achieve this, cancerous tissue begins to spread angiogenic factors in the environment, which enable the sprouting of new vessels.

As Luka Roškar, MD, focuses on minimally invasive treatments, his research focused on finding ways to find less invasive options for endometrial cancer and better treatment options.

The goal of my research is to evaluate the role of angiogenic factors in endometrial cancer and use them as biomarkers for a more accurate, less invasive and faster diagnosis of endometrial cancer and a tailored therapeutic approach, hoping to improve patients' prognosis and reduce the burden of unnecessary invasive treatments.